HUTCHMED Initiates Phase III Trial of HMPL-760

Summary by AI BETAClose X

HUTCHMED has initiated a registrational Phase III clinical trial in China for HMPL-760, an investigational BTK inhibitor, in combination with R-GemOx for patients with relapsed/refractory diffuse large B-cell lymphoma. This randomized, double-blind, positive-controlled study plans to enroll approximately 240 patients and will evaluate efficacy and safety, with primary endpoints of progression-free survival and overall survival. Previous Phase II results showed encouraging improvements, supporting the advancement of this trial, and HUTCHMED retains worldwide rights to HMPL-760.

Disclaimer*

UK 100

Latest directors dealings